Solid Biosciences Inc
NASDAQ:SLDB
Intrinsic Value
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SLDB.
Solid Biosciences Inc's market capitalization is 344m USD.
SLDB stock price is 9.11 USD.
SLDB.
SLDB. Open DCF Valuation
SLDB. Open Relative Valuation
SLDB has upside potential of 90% compared to the average analyst price target.
Open Wall St Estimates
SLDB's ROE (Return on Equity) has decreased in the last 3 years from -51% to -57%, and is approaching profitability.
SLDB's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -496% to -252%, and is approaching profitability.
SLDB has negative Operating Income for the last twelve months.
SLDB has negative Net Income for the last twelve months.
SLDB's ROE (Return on Equity) for the past 12 months is negative and is equal to -57%.
SLDB's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -252%.
SLDB has negative Free Cash Flow for the last twelve months.
SLDB's D/E (Debt to Equity) is very low and is equal to 0.01.
SLDB has negative three-year average ROE (Return on Equity): -53%. The company is not efficient at transforming stockholders' equity into net income.
SLDB has negative three-year average ROIC (Return on Invested Capital): -404%. The company is not efficient at using invested capital to generate operating income.
SLDB's short-term assets (130m USD) exceed its short-term liabilties (15m USD).
SLDB's long-term assets (165m USD) exceed its long-term liabilties (38m USD).
SLDB has negative Net Debt. This means that the company has more cash and short-term investments (124m USD) than debt (1m USD).
SLDB's Altman Z-Score is very low and is equal to -4.12.
Fundamental Analysis
Solid Biosciences Inc
Balance Sheet Decomposition
Solid Biosciences Inc
| Current Assets | 129.7m |
| Cash & Short-Term Investments | 123.6m |
| Other Current Assets | 6.1m |
| Non-Current Assets | 35.2m |
| PP&E | 33.2m |
| Other Non-Current Assets | 2m |
| Current Liabilities | 14.5m |
| Accounts Payable | 2m |
| Accrued Liabilities | 12m |
| Other Current Liabilities | 493k |
| Non-Current Liabilities | 23.9m |
| Long-Term Debt | 1.2m |
| Other Non-Current Liabilities | 22.7m |
Earnings Waterfall
Solid Biosciences Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-104.3m
USD
|
|
Operating Income
|
-104.3m
USD
|
|
Other Expenses
|
8.3m
USD
|
|
Net Income
|
-96m
USD
|
Free Cash Flow Analysis
Solid Biosciences Inc
SLDB Profitability Score
Profitability Due Diligence
Solid Biosciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Solid Biosciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
SLDB Solvency Score
Solvency Due Diligence
Solid Biosciences Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Solid Biosciences Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SLDB Price Targets Summary
Solid Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
SLDB
is 17.34 USD
with a low forecast of 12.12 USD and a high forecast of 22.05 USD.
Ownership
SLDB Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SLDB Price
Solid Biosciences Inc
| Average Annual Return | -33.1% |
| Standard Deviation of Annual Returns | 74.33% |
| Max Drawdown | -99% |
| Market Capitalization | 344m USD |
| Shares Outstanding | 37 756 900 |
| Percentage of Shares Shorted | 3.35% |
Company Profile
Solid Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2018-01-26. Duchenne is a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are its gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. SGT-001 is its lead gene transfer candidate and utilizes an adeno-associated virus (AAV)9 vector. In addition to its gene transfer candidates, it has development programs focusing on platform technologies, including dual gene expression, a technology that allows it to package multiple transgenes into one vector, as well as capsids. The company is developing SGT-001 for the treatment of Duchenne through a single intravenous administration.
You don't have any saved screeners yet
